Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Constellation Pharmaceuticals initiated with a Market Perform at JMP Securities » 14:48
06/24/20
06/24
14:48
06/24/20
14:48
CNST

Constellation Pharmaceuticals

$30.88 /

+0.53 (+1.75%)

JMP Securities analyst…

JMP Securities analyst Reni Benjamin initiated coverage of Constellation Pharmaceuticals with a Market Perform rating and $36 price target. Nonetheless, the analyst acknowledged in a research note before market open that the latest update from the MANIFEST study released during the 2020 EHA annual congress, suggests that CPI-0610/ruxolitinib combination merits evaluation against ruxolitinib monotherapy in an upcoming Phase III study given the 60% SVR35 and 70% TSS50 response rates at week 24. Importantly, these data represent a comfortable margin over what ruxolitinib has historically achieved with about 42% SVR35 and 46% TSS50 response rates at week 24, Benjamin added. On the safety side, the analyst points out that the current profile of the CPI-0610/ruxolitinib combination therapy appears to be even better than ruxolitinib alone. The factor holding Benjamin back from a more favorable valuation is the potential size of the commercial market for CPI-0610.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$30.88 /

+0.53 (+1.75%)

CNST Constellation Pharmaceuticals
$30.88 /

+0.53 (+1.75%)

06/12/20 RBC Capital
Constellation Pharmaceuticals data better than the prior cut, says RBC Capital
05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$30.88 /

+0.53 (+1.75%)

Syndicate
Constellation Pharmaceuticals 5.5M share Secondary priced at $35.00 » 20:30
06/16/20
06/16
20:30
06/16/20
20:30
CNST

Constellation Pharmaceuticals

$35.97 /

-1.74 (-4.61%)

The deal size was…

The deal size was increased from 4.0M to 5.5M shares and priced below the last closing price of $36.01. JPMorgan, Jefferies, Cowen, RBC Capital and SunTrust are acting as joint book running managers for the offering.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$35.97 /

-1.74 (-4.61%)

CNST Constellation Pharmaceuticals
$35.97 /

-1.74 (-4.61%)

06/12/20 RBC Capital
Constellation Pharmaceuticals data better than the prior cut, says RBC Capital
05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$35.97 /

-1.74 (-4.61%)

  • 17
    Jun
Syndicate
Constellation announces offering of 4M shares of common stock » 16:03
06/15/20
06/15
16:03
06/15/20
16:03
CNST

Constellation Pharmaceuticals

$38.43 /

+3.84 (+11.10%)

Constellation…

Constellation Pharmaceuticals announced that it has commenced an underwritten public offering of 4M shares of its common stock. J.P. Morgan, Jefferies, Cowen, and RBC Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as lead manager and Baird is acting as co-manager for the offering.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$38.43 /

+3.84 (+11.10%)

CNST Constellation Pharmaceuticals
$38.43 /

+3.84 (+11.10%)

06/12/20 RBC Capital
Constellation Pharmaceuticals data better than the prior cut, says RBC Capital
05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$38.43 /

+3.84 (+11.10%)

Recommendations
Constellation Pharmaceuticals data better than the prior cut, says RBC Capital » 13:35
06/12/20
06/12
13:35
06/12/20
13:35
CNST

Constellation Pharmaceuticals

$32.89 /

-1.26 (-3.69%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams notes that Constellation Pharmaceuticals shares are trading down 8% despite Phase II data from its lead program CPI-610 that he thinks looked better than the prior cut and solidify the likelihood that the agent will succeed in Phase III. The analyst believes the Street reaction presents a buying opportunity.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$32.89 /

-1.26 (-3.69%)

CNST Constellation Pharmaceuticals
$32.89 /

-1.26 (-3.69%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$32.89 /

-1.26 (-3.69%)

Hot Stocks
Constellation Pharmaceuticals trading resumes  09:43
06/12/20
06/12
09:43
06/12/20
09:43
CNST

Constellation Pharmaceuticals

$34.15 /

+ (+0.00%)

 
ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$34.15 /

+ (+0.00%)

CNST Constellation Pharmaceuticals
$34.15 /

+ (+0.00%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$34.15 /

+ (+0.00%)

Hot Stocks
Constellation Pharmaceuticals trading halted, volatility trading pause  09:38
06/12/20
06/12
09:38
06/12/20
09:38
CNST

Constellation Pharmaceuticals

$34.15 /

-0.6 (-1.73%)

 
ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

Hot Stocks
Constellation Pharmaceuticals provides MANIFEST trial update at EHA » 06:33
06/12/20
06/12
06:33
06/12/20
06:33
CNST

Constellation Pharmaceuticals

$34.15 /

-0.6 (-1.73%)

Constellation…

Constellation Pharmaceuticals announced that three posters relating to the MANIFEST clinical trial of CPI-0610 in myelofibrosi, or MF, were published online in association with the European Hematology Association, or EHA, annual meeting. The data in these posters are based on a data cutoff of April 17 and reflect an analysis of clinical activity in 51 first-line, or 1L, and 73 second-line, or 2L, patients. Overall, 37 of 51 evaluable patients achieved a 35% reduction in spleen volume, or SVR35, at 12 weeks and had a median spleen volume reduction of 51%. Sixty-three percent achieved SVR35 at 24 weeks and had a median spleen volume reduction of 53%. Fifty-nine percent achieved a 50% improvement in Total Symptom Score, or TSS50, at 24 weeks and had a median TSS improvement of 64%. No evidence of correlation between SVR35 response and baseline risk status, platelet count, or spleen volume. Twenty-one percent evaluable transfusion-dependent, or TD, patients converted to transfusion independence, or TI, the primary endpoint for cohort 1A. Twenty-four percent evaluable non-TD patients achieved SVR35 and 9 of 19 evaluable non-TD patients achieved TSS50 at 24 weeks. Fifty-eight percent non-TD patients on treatment for at least 12 weeks without any transfusions achieved a greater than or equal to1.5 g/dL mean increase in hemoglobin. Thirty-four percent evaluable TD patients converted to TI, the primary endpoint for cohort 2A. Twenty-two percent evaluable non-TD patients achieved SVR35 and 37% evaluable non-TD patients achieved TSS50 at 24 weeks. CPI-0610 in MANIFEST, both as monotherapy and in combination with ruxolitinib and in both JAK-inhibitor-naive and JAK-inhibitor-experienced and -ineligible patients, was generally well tolerated. Among the most common treatment-emergent adverse events, or TEAEs, for CPI-0610 monotherapy in 43 safety-evaluable patients in Arm 1, those that were Grade 3 were thrombocytopenia, anemia, diarrhea and respiratory tract infection. Six patients discontinued treatment because of TEAEs. There were no Grade 4 or Grade 5 TEAEs. Among the most common TEAEs in 70 safety-evaluable patients in Arm 2, those that were Grade 3 were thrombocytopenia, anemia, fatigue, diarrhea, respiratory tract infections, nausea and abdominal pain. Grade 4 TEAEs included thrombocytopenia and anemia. Seven patients discontinued treatment due to TEAEs, including four Grade 5 TEAEs, which were acute kidney injury, traumatic subdural hematoma, brain stem hemorrhage and disease progression. Among the most common TEAEs in 64 safety-evaluable patients in Arm 3, those that were Grade 3 were anemia, respiratory tract infections and thrombocytopenia. Grade 4 TEAEs included thrombocytopenia, anemia and respiratory tract infection. Four patients discontinued treatment due to TEAEs, including two Grade 5 TEAEs, each due to multi-organ failure due to sepsis. Constellation announced that it plans to prioritize further clinical development of its next-generation EZH2 inhibitor CPI-0209. The decision is based on a recent data cut and review of ProSTAR, the ongoing Phase 1b/2 clinical study evaluating CPI-1205, a small-molecule inhibitor of EZH2, combined with enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer. The data did not demonstrate the definitive signal of activity necessary to advance the program into pivotal studies in mCRPC. A full data set from ProSTAR will be presented at a future medical meeting.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$34.15 /

-0.6 (-1.73%)

Hot Stocks
Constellation Pharmaceuticals appoints Jeffrey Humphrey as CMO » 08:03
06/08/20
06/08
08:03
06/08/20
08:03
CNST

Constellation Pharmaceuticals

$37.31 /

-0.27 (-0.72%)

Constellation…

Constellation Pharmaceuticals announced that Jeffrey Humphrey, M.D., will join Constellation Pharmaceuticals as CMO. Most recently he was Chief Development Officer at Kyowa Kirin. Adrian Senderowicz, M.D., Constellation's current CMO, will transition to the role of Senior Advisor, where he will continue to advise Constellation on initiatives in research and development, translational science and corporate strategy. The appointment of Dr. Humphrey as CMO and transition of Dr. Senderowicz to a Senior Advisor of Constellation will be effective as of June 22, 2020.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$37.31 /

-0.27 (-0.72%)

CNST Constellation Pharmaceuticals
$37.31 /

-0.27 (-0.72%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$37.31 /

-0.27 (-0.72%)

Over a month ago
Conference/Events
Constellation Pharmaceuticals participates in a conference call with JPMorgan » 09:25
05/18/20
05/18
09:25
05/18/20
09:25
CNST

Constellation Pharmaceuticals

$43.50 /

+0.06 (+0.14%)

Healthcare Analyst Rama…

Healthcare Analyst Rama holds a conference call with CEO Raythatha on May 18 at 10 am hosted by JPMorgan.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

Conference/Events
Constellation Pharmaceuticals participates in a conference call with JPMorgan » 04:55
05/18/20
05/18
04:55
05/18/20
04:55
CNST

Constellation Pharmaceuticals

$43.50 /

+0.06 (+0.14%)

Healthcare Analyst Rama…

Healthcare Analyst Rama holds a conference call with CEO Raythatha on May 18 at 10 am hosted by JPMorgan.

ShowHide Related Items >><<
CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

05/07/20 H.C. Wainwright
Constellation price target raised to $75 from $50 at H.C. Wainwright
03/11/20 BMO Capital
Constellation Pharmaceuticals price target lowered to $35 from $42 at BMO Capital
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
02/13/20 SunTrust
Constellation Pharmaceuticals initiated with a Buy at SunTrust
CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

CNST Constellation Pharmaceuticals
$43.50 /

+0.06 (+0.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.